Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
Front Pediatr. 2023 Feb 22;11:1114207. doi: 10.3389/fped.2023.1114207. eCollection 2023.
Front Pediatr. 2023.
PMID: 36911042
Free PMC article.
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.
Alexeeva E, Shingarova M, Dvoryakovskaya T, Lomakina O, Fetisova A, Isaeva K, Chomakhidze A, Chibisova K, Krekhova E, Kozodaeva A, Savostyanov K, Pushkov A, Zhanin I, Demyanov D, Suspitsin E, Belozerov K, Kostik M.
Alexeeva E, et al. Among authors: krekhova e.
Front Med (Lausanne). 2023 Nov 15;10:1257045. doi: 10.3389/fmed.2023.1257045. eCollection 2023.
Front Med (Lausanne). 2023.
PMID: 38034538
Free PMC article.
Item in Clipboard
Cite
Cite